<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216311412231</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216311412231</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug interactions in palliative care – <italic>it’s more than cytochrome P450</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gaertner</surname><given-names>Jan</given-names></name>
<aff id="aff1-0269216311412231">Department of Palliative Medicine, University Hospital Cologne, Germany; Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Germany; Clinical Trials Center Cologne, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Ruberg</surname><given-names>Klaus</given-names></name>
<aff id="aff2-0269216311412231">Kronen Pharmacy, Hospital and Community Pharmacy, Germany; Working Group Pharmacists of the German Association of Palliative Care, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Schlesiger</surname><given-names>Grit</given-names></name>
<aff id="aff3-0269216311412231">Department of Palliative Medicine, University Hospital Cologne, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Frechen</surname><given-names>Sebastian</given-names></name>
<aff id="aff4-0269216311412231">Department of Palliative Medicine, University Hospital Cologne, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Voltz</surname><given-names>Raymond</given-names></name>
<aff id="aff5-0269216311412231">Department of Palliative Medicine, University Hospital Cologne, Germany; Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Germany; Clinical Trials Center Cologne, Germany</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216311412231">Dr Jan Gaertner, Department of Palliative Medicine, University Hospital Cologne, 50924 Cologne, Germany Email: <email>jan.gaertner@uk-koeln.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>6</issue>
<fpage>813</fpage>
<lpage>825</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0269216311412231">
<title>Objective:</title>
<p>This study aims to identify the combination of substances with high potential for drug interactions in a palliative care setting and to provide concise recommendations for physicians.</p>
</sec>
<sec id="section2-0269216311412231">
<title>Methods:</title>
<p>We used a retrospective systematic chart analysis of 200 consecutive inpatients. The recently developed and internationally advocated classification system OpeRational ClAssification of Drug Interactions was applied using the national database of the Federal Union of German Associations of Pharmacists. Charts of patients with potential for severe DDIs were examined manually for clinical relevance.</p>
</sec>
<sec id="section3-0269216311412231">
<title>Results:</title>
<p>In 151 patients (75%) a total of 631 potential drug interactions were identified. Opioids (exception: methadone), non-opioids (exception: non-steroidal anti-inflammatory drugs), benzodiazepines, proton-pump inhibitors, laxatives, co-analgesics (exception: carbamazepine) and butylscopolamine were generally safe. High potential for drug interactions included combinations of scopolamine, neuroleptics, metoclopramide, antihistamines, non-steroidal anti-inflammatory drugs, (levo-) methadone, amitriptyline, carbamazepine and diuretics. The manual analyses of records from eight patients with risk for severe drug interactions provided no indicator for clinical relevance in these specific patients. Drug interactions attributed to the cytochrome pathway played a minor role (exception: carbamazepine).</p>
</sec>
<sec id="section4-0269216311412231">
<title>Conclusion:</title>
<p>Most relevant drug interactions can be expected with: (i) drugs (inter-) acting via histamine, acetylcholine or dopamine receptors; and (ii) Non-steroidal anti-inflammatory drugs. Even in last hours of life the combination of substances (e.g. anticholinergics) may produce relevant drug interactions (e.g. delirium).</p>
</sec>
<sec id="section5-0269216311412231">
<title>Perspective:</title>
<p>Data on the potential for drug–drug interactions in palliative case is extremely scarce, but drug interactions can be limited if a few facts are considered. A synopsis of the findings of these studies is presented as concise recommendation to minimize drug interactions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Analgesia</kwd>
<kwd>pain</kwd>
<kwd>drug interactions</kwd>
<kwd>cytochrome p450 system</kwd>
<kwd>opioid analgesics</kwd>
<kwd>palliative care</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-0269216311412231" sec-type="intro">
<title>Introduction</title>
<p>Drug or drug–drug interactions (DDIs) have been identified as a relevant problem for pharmacotherapy,<sup><xref ref-type="bibr" rid="bibr1-0269216311412231">1</xref></sup> with a significant impact on morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr2-0269216311412231">2</xref></sup> The importance of this issue was recognized many years ago, but clinicians of different specialties are still busy developing guidelines or algorithms to be implemented in clinical routine.<sup><xref ref-type="bibr" rid="bibr3-0269216311412231">3</xref></sup> Potentials for DDIs have been analysed according to the different classes of agents (e.g.antibiotics, neuroleptics, antiviral drugs) or populations (e.g. elderly, psychiatric or cardiologic patients<sup><xref ref-type="bibr" rid="bibr4-0269216311412231">4</xref></sup>). Patients receiving palliative care (PC) form a unique clinical population and literature relating to DDIs in PC is extremely scarce.<sup><xref ref-type="bibr" rid="bibr1-0269216311412231">1</xref></sup> This article aims to: (i) identify substances with high or low risk of inducing DDI in a PC setting; (ii) compare our findings with the literature; (iii) evaluate the practicability of the recently adapted guidelines for DDI classification;<sup><xref ref-type="bibr" rid="bibr5-0269216311412231">5</xref></sup> and (iv) provide practical guidelines for PC physicians.</p>
</sec>
<sec id="section7-0269216311412231" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section8-0269216311412231">
<title>Data collection</title>
<p>A retrospective systematic analysis of the theoretical potential for DDI in 200 consecutive PC inpatients was performed. The medical records of 200 consecutive inpatients treated on a specialized PC unit between 2007 and 2008 were reviewed retrospectively (e.g. for demographic data, diagnosis, leading symptoms on admission and all substances prescribed throughout the hospitalization). Specifically, <italic>all</italic> drugs that had been prescribed to each patient as regular, on-demand or ‘rescue’ medication during the inpatient stay were included into the study. Notably, the medication for each patient was pooled irrespective of whether:</p>
<list id="list1-0269216311412231" list-type="roman-lower">
<list-item><p>the drugs had been administered concurrently or subsequently (e.g. in case of opioid rotation from morphine to hydromorphone during the hospital stay, both substances would have been included in the list); and</p></list-item>
<list-item><p>a drug had been administered or just prescribed in advance (e.g. as a ‘rescue’ medication) but never been ingested by the patient (e.g. in case of an on-demand prescription of scopolamine for a possible future use in refractory and burdensome death rattle; this drug would still have been included).</p></list-item>
</list>
<p>The reason for this approach was to include <italic>all</italic> drugs in order to ensure the identification of <italic>the entire theoretical potential</italic> for DDI.</p>
</sec>
<sec id="section9-0269216311412231">
<title>DDI identification: ABDA database and its classification system</title>
<p>To identify possible DDIs, the pooled medication list of each patient was checked with the ABDA database in January 2009. The analyses were repeated for actuality in October 2010. In the past, databases classified DDIs according to their pharmacological severity (e.g. ‘major’, ‘moderate’, ‘minor’ or ‘insignificant’), without recommendations of management, and generated long lists of theoretically possible DDIs. This has been criticized as ‘over reporting’ or ‘excessive information’ that often impedes the identification of the really critical DDIs. Some studies have found that between 70% and 91% of the interaction warnings were ignored by the users of the databases, since many interactions remain without therapeutic consequences.<sup><xref ref-type="bibr" rid="bibr6-0269216311412231">6</xref></sup> Therefore, recent developments focus on the development of approaches that ameliorate the identification of clinically relevant DDIs. One of the most recent and most sophisticated classification systems was developed by the Drug Interaction Foundation. This <bold><italic>O</italic></bold><italic>pe</italic><bold><italic>R</italic></bold><italic>ational</italic> <bold><italic>C</italic></bold><italic>l</italic><bold><italic>A</italic></bold><italic>ssification of Drug Interactions</italic> (ORCA) has been adopted by many international pharmaceutical, pharmacists and health care organizations, such as the American Pharmacists Association.<sup><xref ref-type="bibr" rid="bibr7-0269216311412231">7</xref></sup> This DDI classification system does not solely list the possible DDIs, but also provides recommendations on how to deal with this information.</p>
<p>The ORCA classification system has recently also been adopted by the database and DDI identification and classification system of the Federal Union of German Associations of Pharmacists (ABDA) and has been available in Germany since January 2009; it has been implemented in all German generic and hospital pharmacies.<sup><xref ref-type="bibr" rid="bibr8-0269216311412231">8</xref></sup></p>
<p>The ABDA system classifies potential DDIs according to the recommended therapeutic consequences<sup><xref ref-type="bibr" rid="bibr7-0269216311412231">7</xref></sup> and reports six classes (<xref ref-type="table" rid="table1-0269216311412231">Table 1</xref>). These six ABDA classes are based on the four ORCA categories, whereby the ABDA system differentiates the ORCA category ‘Minimize risk’ by the use of three further classes (classes 3–5). Besides this classification, the DDI reporting system generates a monograph that provides veryspecific information about the specific DDI type (e.g.pharmacodynamic, pharmacokinetic, etc.), potential clinical effects and recommendations about how to deal with the suspected DDI.</p>
<table-wrap id="table1-0269216311412231" position="float">
<label>Table 1.</label>
<caption>
<p>Overview of identified drug–drug interactions (DDIs)</p>
</caption>
<graphic alternate-form-of="table1-0269216311412231" xlink:href="10.1177_0269216311412231-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Class</th>
<th align="left">ABDA<sup><xref ref-type="table-fn" rid="table-fn1-0269216311412231">a</xref></sup> description</th>
<th align="left">DDI reports</th>
<th align="left">Pts affected<sup><xref ref-type="table-fn" rid="table-fn6-0269216311412231">f</xref></sup></th>
<th align="left">Drug/drug combination</th>
<th align="left">DDI reports</th>
<th align="left">Pts affected</th>
<th align="left">DDI Type</th>
<th align="left">Clinical effect</th>
</tr>
<tr>
<th/>
<th/>
<th align="left"><italic>n</italic> (%) of 631</th>
<th align="left"><italic>m</italic> (%) of 200</th>
<th align="left">for class 1/2: every found, 3/4: from <italic>m</italic> ≥ 8 patients affected</th>
<th align="left"><italic>n</italic> (%) of 631</th>
<th align="left"><italic>m</italic>(%) of 200</th>
<th align="left">pharmacodynamic/pharmacokinetic</th>
<th align="left">according to ABDA database</th>
</tr>
<tr>
<th align="left">1–6</th>
<th align="left">Total</th>
<th align="left">631 (100.0)</th>
<th align="left">151 (75.5)</th>
<th/>
<th/>
<th/>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Contraindicated (serious events likely)</td>
<td>3 (0.5)</td>
<td>3 (1.5)</td>
<td>Potassium salts/potassium-sparing diuretics</td>
<td>3 (0.5)</td>
<td>3 (1.5)</td>
<td>Dynamic, pos. addition</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td rowspan="4">2</td>
<td rowspan="4">Contraindicated as a precaution</td>
<td rowspan="4">7 (1.1)</td>
<td rowspan="4">5 (2.5)</td>
<td>Opioid agonists/opioid partial agonists</td>
<td>4 (0.6)</td>
<td>2 (1.0)</td>
<td>Dynamic, neg. addition</td>
<td>Reduced opioid effects</td>
</tr>
<tr>
<td>Azole antimycotics/carbamazepine</td>
<td>1 (0.2)</td>
<td>1 (0.5)</td>
<td>Kinetic, metabolism: CYP 3A4</td>
<td>Increased plasma level carbamazepine, less antimycotic effects</td>
</tr>
<tr>
<td>HIV-protease inhibitors/proton pump inhibitors</td>
<td>1 (0.2)</td>
<td>1 (0.5)</td>
<td>Kinetic, reduced resorption</td>
<td>Less bioavailability HIV protease inhibitors</td>
</tr>
<tr>
<td>Midazolam, oral/carbamazepine, phenytoine</td>
<td>1 (0.2)</td>
<td>1 (0.5)</td>
<td>Kinetic, metabolism</td>
<td>Reduced sedative effects on oral midazolam</td>
</tr>
<tr>
<td>3</td>
<td>Monitoring or adjustment necessary</td>
<td>398 (63.1)</td>
<td>139 (69.5)</td>
<td>Neuroleptics/anticholinergics</td>
<td>109 (17.3)</td>
<td>84 (42)</td>
<td>Dynamic, pos. addition side effects</td>
<td>Increased anticholinergic effects</td>
</tr>
<tr>
<td rowspan="7"/>
<td rowspan="7"/>
<td rowspan="7"/>
<td rowspan="7"/>
<td>Neuroleptics/dopamine antagonists</td>
<td>75 (11.9)</td>
<td>51 (25.5)</td>
<td>Dynamic, pos. addition side effects</td>
<td>Increased extrapyramidal motoric side effects</td>
</tr>
<tr>
<td>NSAID<sup><xref ref-type="table-fn" rid="table-fn2-0269216311412231">b</xref></sup>/glucocorticoids</td>
<td>39 (6.2)</td>
<td>37 (18.5)</td>
<td>Dynamic, pos. addition side effects</td>
<td>Increased ulcerogenic effects, intestinal bleedings</td>
</tr>
<tr>
<td>H1-blockers<sup><xref ref-type="table-fn" rid="table-fn3-0269216311412231">c</xref></sup>/neuroleptics</td>
<td>22 (3.5)</td>
<td>19 (9.5)</td>
<td>Dynamic, pos. addition side effects</td>
<td>Increased risk of ventricular tachycardia (QT<sub>c</sub>-prolonging drugs)</td>
</tr>
<tr>
<td>Opioids/enzyme inducers<sup><xref ref-type="table-fn" rid="table-fn4-0269216311412231">d</xref></sup></td>
<td>18 (2.9)</td>
<td>13 (6.5)</td>
<td>Kinetic, metabolism: CYP 3A4</td>
<td>Reduced opioid effects (excl.: hydromorphone)</td>
</tr>
<tr>
<td>Antidiabetics/glucocorticoids</td>
<td>15 (2.4)</td>
<td>12 (6.0)</td>
<td>Dynamic</td>
<td>Risk of hyperglycemia (increased blood sugar level, reduced insulin sensitivity due to glucocorticoids)</td>
</tr>
<tr>
<td>Glucocorticoids<sup><xref ref-type="table-fn" rid="table-fn5-0269216311412231">e</xref></sup>/enzyme inducers<sup><xref ref-type="table-fn" rid="table-fn3-0269216311412231">c</xref></sup></td>
<td>11 (1.7)</td>
<td>11 (5.5)</td>
<td>Kinetic metabolism: CYP 3A4</td>
<td>Decreased effects on glucocorticoids</td>
</tr>
<tr>
<td>Tricyclic antidepressants/neuroleptics</td>
<td>16 (2.5)</td>
<td>10 (5.0)</td>
<td>Dynamic pos. addition side effects</td>
<td>Increased risk of ventricular tachycardia and other side effects, esp. poor metabolizers CYP 2D6</td>
</tr>
<tr>
<td rowspan="2">4</td>
<td rowspan="2">Monitoring or adjustment necessary in certain cases</td>
<td rowspan="2">48 (7.6)</td>
<td rowspan="2">29 (14.5)</td>
<td>NSAID<sup><xref ref-type="table-fn" rid="table-fn2-0269216311412231">b</xref></sup>/beta-blockers</td>
<td>11 (1.7)</td>
<td>10 (5.0)</td>
<td>Dynamic effect unknown</td>
<td>Decreased hypotensive effects</td>
</tr>
<tr>
<td>Kaluretic diuretics/NSAID<sup><xref ref-type="table-fn" rid="table-fn2-0269216311412231">b</xref></sup></td>
<td>11 (1.7)</td>
<td>8 (4.0)</td>
<td>Dynamic increased vascular tone</td>
<td>Decreased diuretic and hypotensive effects</td>
</tr>
<tr>
<td>5</td>
<td>Monitor as a precaution</td>
<td>175 (27.7)</td>
<td>76 (38.0)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>6</td>
<td>No measures required</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269216311412231">
<label>a</label>
<p>Federal Union of German Associations of Pharmacists.</p>
</fn>
<fn id="table-fn2-0269216311412231">
<label>b</label>
<p>Non-steroidal anti-inflammatory drugs.</p>
</fn>
<fn id="table-fn3-0269216311412231">
<label>c</label>
<p>Histamine H1 antagonists.</p>
</fn>
<fn id="table-fn4-0269216311412231">
<label>d</label>
<p>Carbamazepine for example.</p>
</fn>
<fn id="table-fn5-0269216311412231">
<label>e</label>
<p>Mostly dexamethasone.</p>
</fn>
<fn id="table-fn6-0269216311412231">
<label>f</label>
<p>Multiple entries possible per patient, thus the count of its respective class does not sum up to 151.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The first four classes (classes 1–4) remained for detailed analyses because in these cases:</p>
<list id="list2-0269216311412231" list-type="roman-lower">
<list-item><p>the DDI may even arise with the correct use of the drug; and</p></list-item>
<list-item><p>it is to be expected that the DDI will alter the efficacy/toxicity of a drug to such an extent that interventions by the treating physician are recommended according to the DDI report.</p></list-item>
</list>
</sec>
<sec id="section10-0269216311412231">
<title>In-depth analysis of class 1 and 2 DDI reports</title>
<p>In addition to identifying theoretical potentials for DDIs, the records of those patients who were affected by class 1 and 2 DDIs were manually examined in order to look for the clinical relevance of the potential DDI and evidence for factual DDI-related adverse effects.</p>
</sec>
<sec id="section11-0269216311412231">
<title>RED, YELLOW and GREEN flagging</title>
<p>To enhance comprehensibility, an easy to interpret score was provided for all drugs that had been prescribed to at least 10 patients each. Each time a drug was involved in a DDI that required therapeutic action (classes 1–4), it was given one point in the scoring system. The total number of points was then divided by the number of patients who had been prescribed this drug. The resulting ratio (‘<italic>flag score</italic>’) was then used to distinguish the substances’ potential for DDIs once prescribed and was classified as follows:</p>
<p>‘RED FLAG’: flag score ≥50 – beware of therapeutically relevant DDI, avoid this drug if possible;</p>
<p>‘YELLOW FLAG’: flag score 25–50 – consider alternatives/discontinuation if possible;</p>
<p>‘GREEN FLAG’: flag score 0–25 – no serious clinical events due to DDI are expected in general.</p>
<p>The only substance that was not found in the ABDA database at the time of the interactions analysis was cyclizine. DDI checking was thus restricted to the Thomson Healthcare Inc. DRUGDEX© System.<sup><xref ref-type="bibr" rid="bibr9-0269216311412231">9</xref></sup> The only confirmed DDI with cyclizine in DRUGDEX was the combination with procarbazine, an oral cytotoxic agent. On the other hand, cyclizine is an H1-antihistaminic agent, so theoretically the same DDI should be possible as with dimenhydrinate. Therefore, based on the findings of other studies,<sup><xref ref-type="bibr" rid="bibr10-0269216311412231">10</xref></sup> the results of dimenhydrinate are assumed to be similar to cyclizine. This has been marked specifically in the text and tables, and also explicitly denoted as a limitation of this study.</p>
</sec>
</sec>
<sec id="section12-0269216311412231" sec-type="results">
<title>Results</title>
<sec id="section13-0269216311412231">
<title>Demography, symptom burden and medication</title>
<p>The medical records of 200 consecutive inpatients treated on a specialized PC unit between 2007 and 2008 were reviewed retrospectively. Of these patients, 181 suffered from advanced cancer (solid tumours); in 13 cases the underlying disease was haematological and six were admitted due to non-(haemato-) oncological diseases (multiple sclerosis [three patients], amyotrophic lateral sclerosis, chronic obstructive pulmonary disease, renal failure [one patient each]). The median age of the patients was 64 years (range 20–87 years). The most common symptoms leading to admission to the PC ward were pain (72%), dyspnoea (63%), nausea (47%), vomiting (13%) and weakness (10%).</p>
<p>A total of 14 (median) different substances (range 2–25) was prescribed to each patient during the course of the entire hospital stay. Of these, nine (range 0–20) substances were prescribed on a regular basis (‘by the clock’) and seven (range 2–13) as on-demand (‘rescue’) medication.</p>
<p>The most commonly prescribed substances were lorazepam, scopolamine and morphine. These three were prescribed (not necessarily ingested; see methods section) in more than 80% of the patients at least once throughout the hospital stay. Of these three substances, both lorazepam and scopolamine had been (almost ‘routinely’) prescribed for all patients on admission as an on-demand medication (‘rescue’) medication for ‘emergency’ situations and end of life.</p>
<p>Dexamethasone, pantoprazole, cyclizine and metamizole (dipyrone) were prescribed in more than 60%, followed by metoclopramide, macrogol, temazepam and sodium picosulfate in more than 40%, followed by hydromorphone, haloperidol, dimenhydrinate, ibuprofen and fentanyl in more than 20%.</p>
</sec>
<sec id="section14-0269216311412231">
<title>Drug interactions</title>
<p>In 151 patients (75%) potential DDIs were identified (<xref ref-type="table" rid="table1-0269216311412231">Table 1</xref>). Overall the ABDA system reported for these 151 cases 631 theoretically possible DDIs. Hereof, 456DDIs were assigned to the therapeutically relevant classes 1–4.</p>
<p>Only three class 1 DDIs (recommendation: <italic>contraindicated</italic>) were identified regarding the combination of<italic>potassium salts</italic> and <italic>potassium-sparing diuretics</italic> (e.g.spironolactone). A manual evaluation of the medical records of the patients reported to be at risk is provided in the next section.</p>
<p>For class 2 (recommendation: <italic>contraindicated as a precaution</italic>) four different DDIs were reported for seven patients, concerning the combination of <italic>opioids</italic> with <italic>partial agonists</italic> (e.g. buprenorphine) in two patients. A manual evaluation of the medical records of the patients reported to be at risk is provided in the next section.</p>
<p>In class 3 (recommendation: <italic>monitoring or adjustment necessary</italic>) the four most frequently identified DDIs were related to: (i) the combinations of <italic>neuroleptics</italic> and <italic>anticholinergics</italic> (84 patients [42%]); (ii) <italic>neuroleptics</italic> and <italic>dopamine antagonists</italic> (e.g. metoclopramide) (51 patients [25%]); (iii) <italic>non-steroidal anti-inflammatory drugs</italic> (NSAIDs) and <italic>glucocorticoids</italic> (37 patients [19%]); and (iv) <italic>H1 blockers</italic> (e.g. dimenhydrinate) and <italic>neuroleptics</italic> (19 patients [10%]).</p>
<p>The most common class 4 DDIs (recommendation: <italic>monitoring or adjustment necessary in certain cases</italic>) were the combinations of <italic>beta blockers</italic> and <italic>NSAIDs</italic> (10 patients [5%] and further on <italic>kaluretic diuretics</italic> and <italic>NSAIDs</italic> (eight patients [4%]).</p>
<p>The drugs prescribed to at least 10 patients were classified according to the <italic>flag score</italic> to distinguish substances with a high probability of causing DDI-related adverse effects (‘RED FLAGS’, <xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>) from those with a lower risk (‘GREEN FLAGS’, <xref ref-type="table" rid="table3-0269216311412231">Table 3</xref>). Only three substances were labelled with a ‘YELLOW FLAG’: dexamethasone, torsemide and ciprofloxacin.</p>
<table-wrap id="table2-0269216311412231" position="float">
<label>Table 2.</label>
<caption>
<p>Substances with a high potential for drug interactions (‘<italic>red flags</italic>’) affecting at least 10 patients</p>
</caption>
<graphic alternate-form-of="table2-0269216311412231" xlink:href="10.1177_0269216311412231-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Drug</th>
<th align="left" colspan="2">Patients affected (n&gt;10)<hr/></th>
<th align="left">DDI classes 1–4</th>
<th align="left">Flag score<sup><xref ref-type="table-fn" rid="table-fn7-0269216311412231">a</xref></sup>
</th>
</tr>
<tr>
<th align="left"><italic>m</italic></th>
<th align="left">(%[<italic>m</italic> = 200])</th>
<th align="left"><italic>n</italic></th>
<th align="left">RED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scopolamine</td>
<td>189</td>
<td>(94.5)</td>
<td>108</td>
<td>57.1</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>115</td>
<td>(57.5)</td>
<td>80</td>
<td>69.6</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>53</td>
<td>(26.5)</td>
<td>111</td>
<td>209.4</td>
</tr>
<tr>
<td>Dimenhydrinate<sup>b</sup></td>
<td>52</td>
<td>(26.0)</td>
<td>34</td>
<td>65.4</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>41</td>
<td>(20.5)</td>
<td>61</td>
<td>148.8</td>
</tr>
<tr>
<td>Levomepromazine</td>
<td>35</td>
<td>(17.5)</td>
<td>53</td>
<td>151.4</td>
</tr>
<tr>
<td>Melperone</td>
<td>22</td>
<td>(11.0)</td>
<td>48</td>
<td>218.2</td>
</tr>
<tr>
<td>Promethazine</td>
<td>22</td>
<td>(11.0)</td>
<td>16</td>
<td>72.7</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>20</td>
<td>(10.0)</td>
<td>12</td>
<td>60.0</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>17</td>
<td>(8.5)</td>
<td>20</td>
<td>117.6</td>
</tr>
<tr>
<td>Levomethadone</td>
<td>17</td>
<td>(8.5)</td>
<td>18</td>
<td>105.9</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>15</td>
<td>(7.5)</td>
<td>8</td>
<td>53.3</td>
</tr>
<tr>
<td>Insulin</td>
<td>12</td>
<td>(6.0)</td>
<td>12</td>
<td>100.0</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>11</td>
<td>(5.5)</td>
<td>31</td>
<td>281.8</td>
</tr>
<tr>
<td>Furosemide</td>
<td>11</td>
<td>(5.5)</td>
<td>6</td>
<td>54.5</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>11</td>
<td>(5.5)</td>
<td>6</td>
<td>54.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0269216311412231">
<label>a</label>
<p>Flag score: number of DDIs class 1–4 per patients exposed.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0269216311412231" position="float">
<label>Table 3.</label>
<caption>
<p>Substances with a low potential for drug interactions (‘<italic>green flags</italic>’) affecting at least 20 patients</p>
</caption>
<graphic alternate-form-of="table3-0269216311412231" xlink:href="10.1177_0269216311412231-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Drug</th>
<th align="left" colspan="2">Patients affected (<italic>n</italic> &gt; 20)<hr/></th>
<th align="left">DDI classes 1–4</th>
<th align="left">Flag score<sup><xref ref-type="table-fn" rid="table-fn8-0269216311412231">a
</xref></sup></th>
</tr>
<tr>
<th align="left"><italic>m</italic></th>
<th align="left">(%[<italic>m</italic> = 200])</th>
<th align="left"><italic>n</italic></th>
<th align="left">GREEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lorazepam</td>
<td>198</td>
<td>(99.0)</td>
<td>6</td>
<td>3.0</td>
</tr>
<tr>
<td>Morphine</td>
<td>166</td>
<td>(83.0)</td>
<td>15</td>
<td>9.0</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>138</td>
<td>(69.0)</td>
<td>6</td>
<td>4.3</td>
</tr>
<tr>
<td>Cyclizine<sup><xref ref-type="table-fn" rid="table-fn9-0269216311412231">b</xref></sup></td>
<td>135</td>
<td>(67.5)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Dipyrone (metamizole)</td>
<td>127</td>
<td>(63.5)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Macrogol</td>
<td>97</td>
<td>(48.5)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Temazepam</td>
<td>96</td>
<td>(48.0)</td>
<td>3</td>
<td>3.1</td>
</tr>
<tr>
<td>Sodium picosulfate</td>
<td>86</td>
<td>(43.0)</td>
<td>2</td>
<td>2.3</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>74</td>
<td>(37.0)</td>
<td>2</td>
<td>2.7</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>40</td>
<td>(20.0)</td>
<td>3</td>
<td>7.5</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>37</td>
<td>(18.5)</td>
<td>2</td>
<td>5.4</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>36</td>
<td>(18.0)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>35</td>
<td>(17.5)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Paracetamol (acetaminophen)</td>
<td>33</td>
<td>(16.5)</td>
<td>7</td>
<td>21.2</td>
</tr>
<tr>
<td>Enoxaparine</td>
<td>31</td>
<td>(15.5)</td>
<td>3</td>
<td>9.7</td>
</tr>
<tr>
<td>Butylscopolamine</td>
<td>28</td>
<td>(14.0)</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Flunitrazepam</td>
<td>28</td>
<td>(14.0)</td>
<td>1</td>
<td>3.6</td>
</tr>
<tr>
<td>Diazepam</td>
<td>27</td>
<td>(13.5)</td>
<td>3</td>
<td>11.1</td>
</tr>
<tr>
<td>Distigmine</td>
<td>22</td>
<td>(11.0)</td>
<td>3</td>
<td>13.6</td>
</tr>
<tr>
<td>L-thyroxine</td>
<td>22</td>
<td>(11.0)</td>
<td>1</td>
<td>4.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0269216311412231">
<label>a</label>
<p>Flag score: number of DDIs class 1–4 per patients exposed.</p>
</fn>
<fn id="table-fn9-0269216311412231">
<label>b</label>
<p>Cyclizine was not part of the German database. The only confirmed interaction in DRUGDEX was the combination with procarbazine, an oral cytotoxic agent. Cyclizine is an H1-antihistaminic agent, so in this case comparability for example to dimenhydrinate can be assumed. Still, the evidence base for this approach is scarce.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0269216311412231">
<title>Interactions via the cytochrome P450 pathway</title>
<p>Of all different mechanisms associated with DDIs, the cytochrome P450 (CYP) pathway has received the most attention, although most of the hypotheses rely on in vitro or pharmaceutical analyses. Out of the 456 reports of class 1–4 DDIs, only 43 (9%) could be attributed to a CYP in 38 patients (19%). None of these DDIs was involved in class 1 and only one in class 2 DDI (azole antimycotics and carbamazepine). Thus, the majority (88%) of the CYP DDIs could be attributed toclass 3, for example, <italic>opioids</italic> with <italic>enzyme inducers</italic> (e.g.carbamazepine) (13 patients), <italic>glucocorticoids</italic> with <italic>enzyme inducers</italic> (11 patients) and <italic>tricyclic antidepressants</italic> (TCAs) with <italic>neuroleptics</italic> (two patients) (<xref ref-type="table" rid="table1-0269216311412231">Table 1</xref>).</p>
</sec>
<sec id="section16-0269216311412231">
<title>In-depth analysis of class 1 and 2 DDI reports</title>
<sec id="section17-0269216311412231">
<title>Class 1</title>
<p>All three patients affected by the class 1 DDI (<italic>potassium salts/potassium-sparing diuretics</italic>) presented low potassium levels, so that the patients’ particular clinical situations justified the co-administration of this combination.</p>
</sec>
<sec id="section18-0269216311412231">
<title>Class 2</title>
<p>An examination of the records for the combination <italic>opioid agonist with opioid partial agonist</italic> (two patients) revealed that in fact morphine or hydromorphone had never been administered concurrently with buprenorphine, but rather it was administered subsequently. Regarding the combination <italic>azole antimycotics</italic> with <italic>carbamazepine</italic>, it became apparent that carbamazepine was prescribed but in fact never been administered. Another DDI concerned the combination <italic>of HIV protease inhibitors</italic> with <italic>proton-pump inhibitors</italic> (PPIs) that might lower the bioavailability of the protease inhibitor. No evidence of DDI-related effects could be found, since the patient was already in a far advanced stage of the disease and confined to bed. Therefore, laboratory measures (e.g. T cell count, virus load) to monitor an effect of the co-administration were not indicated anymore. The administration of protease inhibitors was stopped soon after. Likewise, no evidence of a clinical impact due to DDI could be found for the combination <italic>oral midazolam</italic> with <italic>carbamazepine</italic> (expecting reduced sedative effects), since the dose was raised until its adequate clinical effect in terminal agitation.</p>
</sec>
</sec>
</sec>
<sec id="section19-0269216311412231" sec-type="discussion">
<title>Discussion</title>
<sec id="section20-0269216311412231">
<title>Opioids</title>
<p>Despite their frequent use, strong (World Health Organization (WHO) class III) opioids did not account for a large number of potential DDIs.<sup><xref ref-type="bibr" rid="bibr11-0269216311412231">11</xref>,<xref ref-type="bibr" rid="bibr12-0269216311412231">12</xref></sup> Interestingly, although the majority of original articles concerning DDIs primarily aim to assess the impact of CYP,<sup><xref ref-type="bibr" rid="bibr13-0269216311412231">13</xref></sup> our data showed that opioids subject to CYP metabolism (e.g. fentanyl) accounted for a similar rate of DDIs to that for opioids metabolized by uridine diphosphate glucuronosyl transferase (UGT) (e.g. morphine, hydromorphone). As in other patient populations, the only opioid with a high risk for potential DDIs was (levo-) methadone<sup><xref ref-type="bibr" rid="bibr14-0269216311412231">14</xref></sup> (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>). Its potentially fatal cardiac effects, due to QT<sub>c</sub> interval prolongation and monamino reuptake inhibition, can be exacerbated by TCAs and neuroleptics.<sup><xref ref-type="bibr" rid="bibr14-0269216311412231">14</xref></sup> Electrocardiography has been recommended for patients in opioid-maintenance programs but is rarely used in a PC setting.<sup><xref ref-type="bibr" rid="bibr15-0269216311412231">15</xref></sup> The pathophysiological environment (e.g. hypoproteinemia, hepatic and renal impairment) of PC patients considerably increases the likelihood of some DDIs.<sup><xref ref-type="bibr" rid="bibr16-0269216311412231">16</xref>,<xref ref-type="bibr" rid="bibr17-0269216311412231">17</xref></sup> While strongly protein-bound substances, such as fentanyl and buprenorphine, might be prone to DDIs in cases of hypoproteinemia,<sup><xref ref-type="bibr" rid="bibr18-0269216311412231">18</xref></sup> they might be advantageous options in cases of renal impairment.<sup><xref ref-type="bibr" rid="bibr16-0269216311412231">16</xref>,<xref ref-type="bibr" rid="bibr17-0269216311412231">17</xref></sup> A recent publication specifically addressing this topic rated hydromorphone as an ‘excellent choice’ in hepatic impairment.<sup><xref ref-type="bibr" rid="bibr12-0269216311412231">12</xref></sup> Notably, it is reported that CYP3A4 inhibitors (e.g. azole antimycotics, diltiazem, etc.) may enhance fentanyl toxicity (e.g. delirium) and should be avoided as co-administration.<sup><xref ref-type="bibr" rid="bibr19-0269216311412231">19</xref>,<xref ref-type="bibr" rid="bibr20-0269216311412231">20</xref></sup>
</p>
<p>Dihydrocodeine (DHC), the most frequently applied weak (WHO II) opioid, was generally safe in our evaluation (flag score: 0). In accordance with a recent publication,<sup><xref ref-type="bibr" rid="bibr21-0269216311412231">21</xref></sup> DHC should be preferred over tramadol or codeine with regard to DDI-related adverse effects, since analgesia is independent of CYP 2D6.<sup><xref ref-type="bibr" rid="bibr21-0269216311412231">21</xref>,<xref ref-type="bibr" rid="bibr22-0269216311412231">22</xref></sup> Moreover, in comparison with tramadol, there is only little risk of serotonin syndrome when co-administered with selective serotonin reuptake inhibitors (SSRIs).<sup><xref ref-type="bibr" rid="bibr12-0269216311412231">12</xref>,<xref ref-type="bibr" rid="bibr21-0269216311412231">21</xref>,<xref ref-type="bibr" rid="bibr23-0269216311412231">23</xref></sup> Overall, weak opioids were rarely administered in our study. Thus, data is limited.</p>
</sec>
<sec id="section21-0269216311412231">
<title>Non-opioids</title>
<p>As in other populations, classic NSAIDs (e.g. ibuprofen) are associated with a potentially high risk of DDIs.<sup><xref ref-type="bibr" rid="bibr24-0269216311412231">24</xref></sup> The main reasons for this high risk for DDIs are the potential for additive nephrotoxicity, gastrointestinal ulcers and severe haemorrhage in combination with other drugs (e.g. glucocorticoids or angiotensin-converting enzyme (ACE) inhibitors).<sup><xref ref-type="bibr" rid="bibr25-0269216311412231">25</xref>,<xref ref-type="bibr" rid="bibr26-0269216311412231">26</xref></sup>
</p>
<p>The non-opioid administered most frequently in our department was dipyrone (metamizole). Although the substance (a prodrug) can decrease serum levels of cyclosporine and certain diuretics, its use was rarely associated with potential DDIs. Despite the ongoing controversy about the risk of metamizole-induced agranulocytosis,<sup><xref ref-type="bibr" rid="bibr27-0269216311412231">27</xref></sup> the findings of this study strengthen the clinical observation that the administration of metamizole is favourable, especially if cancer pain treatment requires the long-term use of a non-opioid.<sup><xref ref-type="bibr" rid="bibr27-0269216311412231">27</xref>,<xref ref-type="bibr" rid="bibr28-0269216311412231">28</xref></sup> As in other studies, paracetamol (acetaminophen) also presented a good safety profile (<xref ref-type="table" rid="table3-0269216311412231">Table 3</xref>), despite being slightly less effective in pain relief than other non-opioids.<sup><xref ref-type="bibr" rid="bibr29-0269216311412231">29</xref>,<xref ref-type="bibr" rid="bibr30-0269216311412231">30</xref></sup> Due to its safety profile (flag score: 0), the potassium channel inhibitor flupirtine may be considered, particularly in musculoskeletal pain<sup><xref ref-type="bibr" rid="bibr31-0269216311412231">31</xref></sup> and for patients with contraindications to NSAIDs<sup><xref ref-type="bibr" rid="bibr32-0269216311412231">32</xref></sup> and dipyrone.</p>
</sec>
<sec id="section22-0269216311412231">
<title>Steroids</title>
<p>As in other publications, three out of four patients in this study received steroids (mostly dexamethasone).<sup><xref ref-type="bibr" rid="bibr33-0269216311412231">33</xref></sup> Dexamethasone was associated with a medium risk of inducing relevant DDI (‘<italic>yellow flag</italic>’). Its use exponentially exacerbates the adverse effects of NSAIDs<sup><xref ref-type="bibr" rid="bibr25-0269216311412231">25</xref></sup> (DDI additive toxicity). However, steroids are very often indispensable in the treatment of pain, dyspnoea, nausea and anorexia in PC patients<sup><xref ref-type="bibr" rid="bibr34-0269216311412231">34</xref></sup> and do not exhibit a comparable ulcerogenic potential if not administered together with NSAIDs.<sup><xref ref-type="bibr" rid="bibr25-0269216311412231">25</xref></sup> In clinical practice, we generally aim at discontinuing the steroid by tapering off the dose once the patient’s symptoms (e.g. pain, dyspnoea, etc.) are well controlled and re-applying a high single morning dose if symptoms arise once more.</p>
</sec>
<sec id="section23-0269216311412231">
<title>Hypnotics</title>
<p>Benzodiazepines accounted for only a small number of potential DDIs despite their widespread use. Even extensively metabolized substances, such as diazepam, did not appear to be problematic (<xref ref-type="table" rid="table3-0269216311412231">Table 3</xref>).</p>
<p>Non-benzodiazepines (e.g. zopiclone) appeared to besafe as well (flag score: 0). In comparison with benzodiazepines, these substances exhibit less potential forthe development of tolerance and receptor down regulation.<sup><xref ref-type="bibr" rid="bibr35-0269216311412231">35</xref>,<xref ref-type="bibr" rid="bibr36-0269216311412231">36</xref></sup>
</p>
</sec>
<sec id="section24-0269216311412231">
<title>Antiemetics and neuroleptics</title>
<p>Antiemetics of the antihistamine group were associated with a rather high potential for DDIs (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>). Antiemetics acting via the dopamine pathway generally exhibited a higher risk of potential DDIs (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>). This applies to the dopamine antagonist metoclopramide,<sup><xref ref-type="bibr" rid="bibr37-0269216311412231">37</xref></sup> as well as to neuroleptics with high (e.g. haloperidol) and low (e.g. levomepromazine) potency. Domperidone might be considered as an alternative to metoclopramide with no central DDI-related adverse effects, since it lacks the ability to pass the blood-brain barrier.<sup><xref ref-type="bibr" rid="bibr38-0269216311412231">38</xref>,<xref ref-type="bibr" rid="bibr39-0269216311412231">39</xref></sup> To date, no clear evidence has been presented about the dose-dependent nature of neuroleptics-related DDI. Clinically, it can be assumed that if neuroleptics are administered in low antiemetic doses, their potential for DDI is far less than when they are used in cases of psychosis or delirium. Although neuroleptics are often indispensable, the combination with (i) anticholinergics, (ii) dopamine antagonists and (iii) antihistamines accounts for a large number of potential DDIs that require monitoring or dose adjustment.</p>
</sec>
<sec id="section25-0269216311412231">
<title>Antidepressants</title>
<p>As expected, TCAs (e.g. amitriptyline) are associated with a high risk of DDI (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>), which is mainly due to their anticholinergic activity resulting in increased incidence of delirium, sedation, xerostomia and difficulty inmicturition.<sup><xref ref-type="bibr" rid="bibr40-0269216311412231">40</xref></sup> In particular, the co-administration of other anticholinergic-acting drugs (see below) predisposes to serious DDI-related adverse effects. The cardiotoxic DDI may not be as relevant as in acute care settings, since TCAs in PC are usually prescribed in much lower doses for neuropathic pain. The other antidepressant assessed in this study was mirtazapine, a noradrenergic and specific serotonergic-acting tetracyclic antidepressant (NaSSA). It was generally safe as far as DDIs are concerned (flag score: 7). This is in line with preceding publications that report a favourable DDI profile of mirtazapine.<sup><xref ref-type="bibr" rid="bibr41-0269216311412231">41</xref>,<xref ref-type="bibr" rid="bibr42-0269216311412231">42</xref></sup>
</p>
</sec>
<sec id="section26-0269216311412231">
<title>Laxative and proton-pump inhibitors</title>
<p>Both the use of laxatives and PPIs were identified in this study to be generally safe and a widespread use is recommended, especially as a useful co-administration (for laxatives to opioids<sup><xref ref-type="bibr" rid="bibr43-0269216311412231">43</xref></sup> and for PPI to NSAID and glucocorticoids<sup><xref ref-type="bibr" rid="bibr44-0269216311412231">44</xref>,<xref ref-type="bibr" rid="bibr45-0269216311412231">45</xref></sup>).</p>
</sec>
<sec id="section27-0269216311412231">
<title>Diuretics</title>
<p>These substances were associated with an increased risk of DDI (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>). Although in some situations diuretics can be tried for the treatment of edema, effusions or ascites in PC patients, their effects are often minimal.<sup><xref ref-type="bibr" rid="bibr46-0269216311412231">46</xref></sup> The discontinuation of diuretics is advisable if the patient does not clearly benefit from this treatment. Torsemide exhibited a more favourable DDI profile compared with furosemide (‘<italic>yellow flag</italic>’) and may be more efficacious, especially in patients with advanced congestive heart failure.<sup><xref ref-type="bibr" rid="bibr47-0269216311412231">47</xref><xref ref-type="bibr" rid="bibr48-0269216311412231"/>–<xref ref-type="bibr" rid="bibr49-0269216311412231">49</xref></sup> Still, both substances are loop diuretics, and therefore clinical use should be carefully monitored.</p>
</sec>
<sec id="section28-0269216311412231">
<title>Anticholinergic activity and dose independence</title>
<p>The highest potential for DDIs found in our study was attributed to substances with anticholinergic activity (<xref ref-type="table" rid="table2-0269216311412231">Table 2</xref>). In particular, additive anticholinergic DDI-associated adverse effects (e.g. delirium, psychosis, sedation, xerostomia, urination disorders<sup><xref ref-type="bibr" rid="bibr50-0269216311412231">50</xref></sup>) have to be considered in the case of co-administration of drugs (inter-) acting at cholinergic receptors (e.g. scopolamine, TCAs, neuroleptics, opioids). The ABDA database specifically reports a <italic>dose-independent</italic> risk of serious DDI for the co-administration of haloperidol and scopolamine. Despite a recent Cochrane review, which explicitly identified scopolamine as a potent cause of adverse anticholinergic effects on the central nervous system, such as psychosis, the substance is still frequently used to reduce death rattle or hypersalivation.<sup><xref ref-type="bibr" rid="bibr51-0269216311412231">51</xref></sup> In dying patients, clinicians are unable to determine the prevalence of such symptoms. As reported in the Cochrane review, the issue remains controversial despite the evidence base, since some physicians and nurses are reluctant to relinquish the use of scopolamine. In almost all cases death rattle is not associated with patient burden.<sup><xref ref-type="bibr" rid="bibr52-0269216311412231">52</xref></sup> Therefore the Cochrane recommendations favour non-pharmacologic interventions. If a pharmaceutic intervention is indicated at all, toxicity may be reduced by administrating quaternary anticholinergics (e.g. butylscopolamine, glycopyrrolate) that lack the ability to pass the blood-brain barrier.</p>
</sec>
<sec id="section29-0269216311412231">
<title>Co-analgesics and antiepileptic drugs</title>
<p>Pregabalin was favourable compared with other co-analgesics, such as clonazepam and in particular carbamazepine, that bear a higher risk of DDI (<xref ref-type="table" rid="table2-0269216311412231">Tables 2</xref> and <xref ref-type="table" rid="table3-0269216311412231">3</xref>). Carbamazepine is well known as a potent CYP-inducing and highly interacting drug<sup><xref ref-type="bibr" rid="bibr53-0269216311412231">53</xref></sup> and also a potent cause of life-threatening or symptomatic hyponatremia.<sup><xref ref-type="bibr" rid="bibr4-0269216311412231">4</xref></sup> Clonazepam is a potent enzyme inductor and long-term administration usually leads to decreasing effectiveness due to receptor down regulation.<sup><xref ref-type="bibr" rid="bibr54-0269216311412231">54</xref>,<xref ref-type="bibr" rid="bibr55-0269216311412231">55</xref></sup> Concerning antiepileptic therapy, no drug was used frequently enough (&lt;10 patients) in our patients to provide sufficient data. Theoretically, valproic acid is being increasingly used for seizures due to a lower potential for cytochrome induction compared with phenytoin. Valproate does only modestly inhibit CYP3A4. Levetiracetam is the first antiepileptic with either gabapentin or valproic acid as an ‘add-on’ for uncontrolled seizures. Yet, the evidence base for recommendations in a PC setting is limited.<sup><xref ref-type="bibr" rid="bibr29-0269216311412231">29</xref>,<xref ref-type="bibr" rid="bibr56-0269216311412231">56</xref></sup>
</p>
</sec>
<sec id="section30-0269216311412231">
<title>Bottom line: Recommendations and interdisciplinary approach</title>
<p>We agree with the only other comparable study of Riechelmann et al.,<sup><xref ref-type="bibr" rid="bibr29-0269216311412231">29</xref></sup> who point out the need for comprehensive recommendations for the prevention of DDI in PC. Meanwhile, the new ORCA system provides a valuable tool to focus on potentially relevant DDIs. Still, DDIs cannot be prevented by solely implementing electronic databases in daily routine. Therefore, we provide a synopsis of recommendations based on the results of this study as a ‘roadmap’ (<xref ref-type="table" rid="table4-0269216311412231">Table 4</xref>). In-depth analysis of the potentially severe DDIs reported by the database proved that specific therapeutic consequences should always take into account the patient’s particular therapeutic environment (early or late in the disease, specific parameters [e.g. potassium level, etc.]), the focus of care (life prolonging or quality of life) and current research findings (e.g. the concomitant use of buprenorphine and morphine may be justified in accordance with a recent study,<sup><xref ref-type="bibr" rid="bibr57-0269216311412231">57</xref></sup> despite the ABDA report).</p>
<table-wrap id="table4-0269216311412231" position="float">
<label>Table 4.</label>
<caption>
<p>Roadmap: drug interactions in palliative care — points of interest (POIs)</p>
</caption>
<graphic alternate-form-of="table4-0269216311412231" xlink:href="10.1177_0269216311412231-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Drug</th>
<th align="left">Flag</th>
<th align="left">Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Opioids</bold></td>
<td/>
<td><bold>Generally safe</bold></td>
</tr>
<tr>
<td>Morphine</td>
<td><italic>Green</italic></td>
<td>Favourable</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td><italic>Green</italic></td>
<td>Favourable</td>
</tr>
<tr>
<td>Fentanyl</td>
<td><italic>Green</italic></td>
<td>Beware of high plasma protein binding</td>
</tr>
<tr>
<td>Levomethadone</td>
<td><bold>Red</bold></td>
<td>Potentially fatal cardiac effects</td>
</tr>
<tr>
<td>Tincture of Opium</td>
<td><italic>Green</italic></td>
<td/>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td><italic>Green</italic></td>
<td>Analgesia independent of CYP 2D6 activity i.c.t. tramadol/codeine and only little risk of serotonin syndrome co-administered with SSRI i.c.t. tramadol</td>
</tr>
<tr>
<td colspan="3"><bold>Non-opioids</bold></td>
</tr>
<tr>
<td>Dipyrone (metamizole)</td>
<td><italic>Green</italic></td>
<td>Favourable for long-term use</td>
</tr>
<tr>
<td>NSAID (e.g. ibuprofen)</td>
<td><bold>Red</bold></td>
<td>Beware of long-term use, renal impairment, intestinal and gastric ulcers, hypovolemia; avoid co-administration with ACE inhibitors and steroids</td>
</tr>
<tr>
<td>Paracetamol</td>
<td><italic>Green</italic></td>
<td/>
</tr>
<tr>
<td>Flupirtine</td>
<td><italic>Green</italic></td>
<td/>
</tr>
<tr>
<td colspan="3"><bold>Steroids</bold></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Yellow</td>
<td>Try tapering off, but <bold>often indispensable</bold> apply as single morning dose, risk of peptic ulcers much less than NSAID (but beware of co-administration)</td>
</tr>
<tr>
<td><bold>Hypnotics</bold></td>
<td/>
<td><bold>generally safe</bold></td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td><italic>Green</italic></td>
<td>e.g. Lorazepam, Temazepam, Flunitrazepam, Diazepam</td>
</tr>
<tr>
<td>Zopiclone</td>
<td><italic>Green</italic></td>
<td>Probably no evidence of tolerance</td>
</tr>
<tr>
<td colspan="3"><bold>Co-Analgesics and AED</bold></td>
</tr>
<tr>
<td>Pregabalin</td>
<td><italic>Green</italic></td>
<td>Favourable</td>
</tr>
<tr>
<td>Clonazepam</td>
<td><italic>Green</italic></td>
<td>Beware of enzyme induction and emerging tolerance (benzodiazepine!)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td><bold>Red</bold></td>
<td>Beware of enzyme induction and hyponatremia, 2nd or 3rd generation AED are favourable for antiepileptic therapy</td>
</tr>
<tr>
<td><bold>Neuroleptics</bold></td>
<td/>
<td>High pDDI, but often indispensable; <bold>but low pDDI if administered in antiemetic dose</bold></td>
</tr>
<tr>
<td>High potency</td>
<td><bold>Red</bold></td>
<td>e.g. Haloperidol</td>
</tr>
<tr>
<td>Low potency</td>
<td><bold>Red</bold></td>
<td>e.g. Levomepromazine, Melperone, Promethazine</td>
</tr>
<tr>
<td colspan="3"><bold>Antiemetics</bold></td>
</tr>
<tr>
<td>Dimenhydrinate</td>
<td><bold>Red</bold></td>
<td/>
</tr>
<tr>
<td>Cyclizine<sup><xref ref-type="table-fn" rid="table-fn10-0269216311412231">a</xref></sup></td>
<td><bold>Red</bold></td>
<td>pDDI was assumed to be comparable to dimenhydrinate</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td><bold>Red</bold></td>
<td>Consider Domperidone as an alternative</td>
</tr>
<tr>
<td>Neuroleptics</td>
<td><bold>Red</bold></td>
<td>But low pDDI if given in low antiemetic dose</td>
</tr>
<tr>
<td colspan="3"><bold>Antidepressants</bold></td>
</tr>
<tr>
<td>Mirtazapine (NaSSA)</td>
<td><italic>Green</italic></td>
<td>Favourable DDI profile</td>
</tr>
<tr>
<td>TCA (e.g. Amitriptylin)</td>
<td><bold>Red</bold></td>
<td>Beware of anticholinergic activity (see below: anticholinergics)</td>
</tr>
<tr>
<td><bold>Anticholinergics</bold></td>
<td/>
<td><bold>Highest pDDI</bold>; increased incidence of delirium, psychosis, sedation, xerostomia, urination disorders, especially in case of co-administration of two such drugs</td>
</tr>
<tr>
<td>Scopolamine</td>
<td><bold>Red</bold></td>
<td>DDI may also be relevant as single dose when applied close to death due to uncheckable central side effects (e.g. agitation, delirium), thus consider treating death rattle non-pharmacologically according to Cochrane Review</td>
</tr>
<tr>
<td>Butylscopolamine</td>
<td><italic>Green</italic></td>
<td>Lower pDDI due to lacking central activity</td>
</tr>
<tr>
<td><bold>Proton pump inhibitors</bold></td>
<td/>
<td><bold>Generally safe</bold>, useful co-administration to NSAID and glucocorticoids</td>
</tr>
<tr>
<td/>
<td><italic>Green</italic></td>
<td>e.g. Pantoprazole, Esomeprazole</td>
</tr>
<tr>
<td><bold>Laxatives</bold></td>
<td/>
<td><bold>Generally safe</bold></td>
</tr>
<tr>
<td/>
<td><italic>Green</italic></td>
<td>e.g. Macrogol, Sodium picosulfate</td>
</tr>
<tr>
<td><bold>Diuretics</bold></td>
<td/>
<td><bold>Discontinuation advisable</bold> if the specific patient does not clearly benefit</td>
</tr>
<tr>
<td>Spironolactone</td>
<td><bold>Red</bold></td>
<td/>
</tr>
<tr>
<td>Furosemide</td>
<td><bold>Red</bold></td>
<td/>
</tr>
<tr>
<td>Torsemide</td>
<td>Yellow</td>
<td>Less DDI in this study, may be more efficacious in pts with congestive heart failure</td>
</tr>
<tr>
<td colspan="3"><bold>Others</bold></td>
</tr>
<tr>
<td colspan="2"><bold>Red</bold> Beta-Blockers (e.g., Bisoprolol, Metoprolol)</td>
<td><italic>Green</italic> Bisphosphonates (e.g., Ibandronic acid)</td>
</tr>
<tr>
<td colspan="2"><italic>Green</italic> LMW Heparin (e.g., Enoxaparin)</td>
<td><italic>Green</italic> Ocreotide</td>
</tr>
<tr>
<td colspan="2"><italic>Green</italic> L-Thyroxine</td>
<td><italic>Green</italic> Dietary supplements e.g. amino acids, vitamins, fatty acids</td>
</tr>
<tr>
<td colspan="3"><italic>Green</italic> Distigmine (parasympathomimetic)</td>
</tr>
<tr>
<td colspan="2">Yellow Ciprofloxacin</td>
<td><bold>Red</bold> Insulin</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0269216311412231">
<label>a</label>
<p>Cyclizine was unavailable in the German ABDA database, so the pDDI was assumed to be comparable to <italic>dimenhydrinate</italic>.</p>
</fn>
<fn id="table-fn11-0269216311412231">
<p>i.c.t.: in contrast to, SSRI: selective serotonin reuptake inhibitors (e.g. Sertralin), NSAID: non-steroidal anti-inflammatory drugs, AED: antiepileptic drugs (2nd/3rd gen.: e.g. Levetiracetam); TCA: Tricyclic antidepressants, ACE: angiotensin-converting enzyme, pDDI: potential drug–drug interaction, NaSSA: noradrenergic and specific serotonergic-acting tetracyclic antidepressant</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Summarizing, therapeutically relevant DDIs are particularly expected for drugs interacting with histamine, acetylcholine and dopamine receptors and for NSAIDs.</p>
<p>This study was assessed by an experienced PC pharmacist and a senior PC specialist, following the philosophy of an interdisciplinary approach to PC.<sup><xref ref-type="bibr" rid="bibr58-0269216311412231">58</xref></sup> Accordingly, we consider it advisable for PC teams to establish a consulting cooperation with a PC pharmacist.</p>
</sec>
<sec id="section31-0269216311412231">
<title>Major limitations</title>
<p>Firstly, as in the other study that has addressed this topic so far,<sup><xref ref-type="bibr" rid="bibr29-0269216311412231">29</xref></sup> a major limitation of our study is that the substances included in our evaluation were restricted to those selected through personal, institutional and national routine practice, tradition, experience and availability at our institution. The two studies cannot be compared directly, since the medication used in the patient population examined by Riechelmann et al.<sup><xref ref-type="bibr" rid="bibr29-0269216311412231">29</xref></sup> was also influenced by routine practice and availability in another country. Secondly, the degree of evidence provided by this study is limited by its retrospective design presenting data about <italic>theoretical potentials</italic> for DDIs, since all prescribed drugs are included in the study, irrespective of whether they had been administered together or not (see above). Hence, further studies are needed to quantify the clinical impact of DDIs in a PC setting.</p>
</sec>
<sec id="section32-0269216311412231">
<title>Other limitations of the study</title>
<list id="list3-0269216311412231" list-type="order">
<list-item><p>The approach of this study does not assess dose-related DDIs, since we focus on substance-related DDIs according to the ABDA database. However, it is worth mentioning that dose-independent DDIs have been identified (see above).</p></list-item>
<list-item><p>Since PC is becoming increasingly integrated early in the course of cancer, DDIs between ‘classic’ PC drugs and antineoplastic agents are an emerging topic of interest. Unfortunately, our data do not cover this issue, since antineoplastic agents are seldom indicated in our patients, who are mostly in far advanced stages of their diseases.</p></list-item>
<list-item><p>Cyclizine was unavailable in the database but was analysed via DRUGDEX. Based on these findings, the potential for DDI was assumed to be comparable to dimenhydrinate (another H1 antihistaminic assesses). Although this approach is based on the findings of other studies it remains a postulate.<sup><xref ref-type="bibr" rid="bibr10-0269216311412231">10</xref></sup></p></list-item>
</list>
</sec>
</sec>
<sec id="section33-0269216311412231" sec-type="conclusions">
<title>Conclusions</title>
<p>The present study is the first to provide data following the new international DDI classification in a PC population. The classification system was found to be helpful in reducing the amount of information generated by electronic databases. It is the second study assessing the potential for DDIs in PC patients.</p>
<p>We hope to provide some valuable information for clinical practice. As mentioned previously, prospective studies are still needed to quantify the clinical impact of DDIs in PC patients. We advocate a concise approach, such as the ‘flags’ and ‘road map’ in this study (<xref ref-type="table" rid="table2-0269216311412231">Tables 2</xref><xref ref-type="table" rid="table3-0269216311412231"/>–<xref ref-type="table" rid="table4-0269216311412231">4</xref>). Moreover, we consider it helpful to develop aninterdisciplinary cooperation with specialized PC pharmacists.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The scientific work of the Department of Palliative medicine, University Clinic of Cologne is supported by the Federal Ministry for Education and Science (BMBF 01KN1106). The clinical and academic activities of the Department of Palliative Medicine, University Clinic of Cologne, are substantially supported by the German Cancer Aid (Deutsche Krebshilfe e.V.).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216311412231">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riechelmann</surname><given-names>RP</given-names></name>
<name><surname>Del Giglio</surname><given-names>A</given-names></name>
</person-group>. <article-title>Drug interactions in oncology: how common are they?</article-title> <source>Ann Oncol</source> <year>2009</year>; <volume>20</volume>: <fpage>1907</fpage>–<lpage>1912</lpage>.</citation>
</ref>
<ref id="bibr2-0269216311412231">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juurlink</surname><given-names>DN</given-names></name>
<name><surname>Mamdani</surname><given-names>M</given-names></name>
<name><surname>Kopp</surname><given-names>A</given-names></name>
<name><surname>Laupacis</surname><given-names>A</given-names></name>
<name><surname>Redelmeier</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Drug-drug interactions among elderly patients hospitalized for drug toxicity</article-title>. <source>J Am Med Assoc</source> <year>2003</year>; <volume>289</volume>: <fpage>1652</fpage>–<lpage>1658</lpage>.</citation>
</ref>
<ref id="bibr3-0269216311412231">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horn</surname><given-names>JR</given-names></name>
<name><surname>Hansten</surname><given-names>PD</given-names></name>
<name><surname>Chan</surname><given-names>LN</given-names></name>
</person-group>. <article-title>Proposal for a new tool to evaluate drug interaction cases</article-title>. <source>Ann Pharmacother</source> <year>2007</year>; <volume>41</volume>: <fpage>674</fpage>–<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr4-0269216311412231">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lordos</surname><given-names>EF</given-names></name>
<name><surname>Trombert</surname><given-names>V</given-names></name>
<name><surname>Vogt</surname><given-names>N</given-names></name>
<name><surname>Perrenoud</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Antiepileptic drugs in the treatment of neuropathic pain: drug-to-drug interaction in elderly people</article-title>. <source>J Am Geriatr Soc</source> <year>2009</year>; <volume>57</volume>: <fpage>181</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr5-0269216311412231">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansten</surname><given-names>PD</given-names></name>
<name><surname>Horn</surname><given-names>JR</given-names></name>
<name><surname>Hazlet</surname><given-names>TK</given-names></name>
</person-group>. <article-title>ORCA: OpeRational ClassificAtion of drug interactions</article-title>. <source>J Am Pharm Assoc (Wash)</source> <year>2001</year>; <volume>41</volume>: <fpage>161</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr6-0269216311412231">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weingart</surname><given-names>SN</given-names></name>
<name><surname>Toth</surname><given-names>M</given-names></name>
<name><surname>Sands</surname><given-names>DZ</given-names></name>
<name><surname>Aronson</surname><given-names>MD</given-names></name>
<name><surname>Davis</surname><given-names>RB</given-names></name>
<name><surname>Phillips</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Physicians’ decisions to override computerized drug alerts in primary care</article-title>. <source>Arch Intern Med</source> <year>2003</year>; <volume>163</volume>: <fpage>2625</fpage>–<lpage>2631</lpage>.</citation>
</ref>
<ref id="bibr7-0269216311412231">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nebeker</surname><given-names>JR</given-names></name>
<name><surname>Barach</surname><given-names>P</given-names></name>
<name><surname>Samore</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting</article-title>. <source>Ann Intern Med</source> <year>2004</year>; <volume>140</volume>: <fpage>795</fpage>–<lpage>801</lpage>.</citation>
</ref>
<ref id="bibr8-0269216311412231">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zagermann-Muncke</surname><given-names>P</given-names></name>
</person-group>. <article-title>New ABDA database classification of interactions showing the way through the interactions jungle</article-title>. <source>PharmZtg</source> <year>2009</year>; <volume>2</volume>: <fpage>25</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr9-0269216311412231">
<label>9.</label>
<citation citation-type="web">
<collab>Thomson Reuters</collab>. ‘<article-title>DRUGDEX System</article-title>’, <ext-link ext-link-type="uri" xlink:href="http://www.micromedex.com/products/drugdex/">http://www.micromedex.com/products/drugdex/</ext-link> (<access-date>accessed January 2009 and October 2010</access-date>).</citation>
</ref>
<ref id="bibr10-0269216311412231">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>A</given-names></name>
<name><surname>Yasui-Furukori</surname><given-names>N</given-names></name>
<name><surname>Mihara</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol</article-title>. <source>Ther Drug Monit</source> <year>2003</year>; <volume>25</volume>: <fpage>192</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr11-0269216311412231">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riechelmann</surname><given-names>RP</given-names></name>
<name><surname>Moreira</surname><given-names>F</given-names></name>
<name><surname>Smaletz</surname><given-names>O</given-names></name>
<name><surname>Saad</surname><given-names>ED</given-names></name>
</person-group>. <article-title>Potential for drug interactions in hospitalized cancer patients</article-title>. <source>Canc Chemother Pharmacol</source> <year>2005</year>; <volume>56</volume>: <fpage>286</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr12-0269216311412231">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strouse</surname><given-names>TB</given-names></name>
</person-group>. <article-title>Pharmacokinetic drug interactions in palliative care: focus on opioids</article-title>. <source>J Palliat Med</source> <year>2009</year>; <volume>12</volume>: <fpage>1043</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr13-0269216311412231">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grime</surname><given-names>KH</given-names></name>
<name><surname>Bird</surname><given-names>J</given-names></name>
<name><surname>Ferguson</surname><given-names>D</given-names></name>
<name><surname>Riley</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods</article-title>. <source>Eur J Pharm Sci</source> <year>2009</year>; <volume>36</volume>: <fpage>175</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr14-0269216311412231">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weschules</surname><given-names>DJ</given-names></name>
<name><surname>Bain</surname><given-names>KT</given-names></name>
<name><surname>Richeimer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Actual and potential drug interactions associated with methadone</article-title>. <source>Pain Med</source> <year>2008</year>; <volume>9</volume>: <fpage>315</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr15-0269216311412231">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaertner</surname><given-names>J</given-names></name>
<name><surname>Voltz</surname><given-names>R</given-names></name>
<name><surname>Ostgathe</surname><given-names>C</given-names></name>
</person-group>. <article-title>Methadone: a closer look at the controversy</article-title>. <source>J Pain Symptom Manage</source> <year>2008</year>; <volume>36</volume>: <fpage>e4</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr16-0269216311412231">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murtagh</surname><given-names>FE</given-names></name>
<name><surname>Chai</surname><given-names>MO</given-names></name>
<name><surname>Donohoe</surname><given-names>P</given-names></name>
<name><surname>Edmonds</surname><given-names>PM</given-names></name>
<name><surname>Higginson</surname><given-names>IJ</given-names></name>
</person-group>. <article-title>The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice</article-title>. <source>J Pain Palliat Care Pharmacother</source> <year>2007</year>; <volume>21</volume>: <fpage>5</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr17-0269216311412231">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>H</given-names></name>
<name><surname>Bruckenthal</surname><given-names>P</given-names></name>
</person-group>. <article-title>Implications of opioid analgesia for medically complicated patients</article-title>. <source>Drugs Aging</source> <year>2010</year>; <volume>27</volume>: <fpage>417</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr18-0269216311412231">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lotsch</surname><given-names>J</given-names></name>
<name><surname>Skarke</surname><given-names>C</given-names></name>
<name><surname>Tegeder</surname><given-names>I</given-names></name>
<name><surname>Geisslinger</surname><given-names>G</given-names></name>
</person-group>. <article-title>Drug interactions with patient-controlled analgesia</article-title>. <source>Clin Pharmacokinet</source> <year>2002</year>; <volume>41</volume>: <fpage>31</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr19-0269216311412231">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levin</surname><given-names>TT</given-names></name>
<name><surname>Bakr</surname><given-names>MH</given-names></name>
<name><surname>Nikolova</surname><given-names>T</given-names></name>
</person-group>. <article-title>Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction</article-title>. <source>Gen Hosp Psychiatr</source> <year>2010</year>; <volume>32</volume>: <fpage>648 e649</fpage>–<lpage>648 e610</lpage>.</citation>
</ref>
<ref id="bibr20-0269216311412231">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saari</surname><given-names>TI</given-names></name>
<name><surname>Laine</surname><given-names>K</given-names></name>
<name><surname>Neuvonen</surname><given-names>M</given-names></name>
<name><surname>Neuvonen</surname><given-names>PJ</given-names></name>
<name><surname>Olkkola</surname><given-names>KT</given-names></name>
</person-group>. <article-title>Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl</article-title>. <source>Eur J Clin Pharmacol</source> <year>2008</year>; <volume>64</volume>: <fpage>25</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr21-0269216311412231">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leppert</surname><given-names>W</given-names></name>
</person-group>. <article-title>Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain</article-title>. <source>Curr Drug Metab</source> <year>2010</year>; <volume>11</volume>: <fpage>494</fpage>–<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr22-0269216311412231">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilder-Smith</surname><given-names>CH</given-names></name>
<name><surname>Hufschmid</surname><given-names>E</given-names></name>
<name><surname>Thormann</surname><given-names>W</given-names></name>
</person-group>. <article-title>The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers</article-title>. <source>Br J Clin Pharmacol</source> <year>1998</year>; <volume>45</volume>: <fpage>575</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr23-0269216311412231">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markowitz</surname><given-names>JS</given-names></name>
<name><surname>Devine</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations</article-title>. <source>Ther Drug Monit</source> <year>1997</year>; <volume>19</volume>: <fpage>244</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr24-0269216311412231">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanigan</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Over-the-counter medications and cancer patients: growing awareness of drug-drug interactions</article-title>. <source>Expert Opin Drug Metab Toxicol</source> <year>2009</year>; <volume>5</volume>: <fpage>105</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr25-0269216311412231">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobata</surname><given-names>Y</given-names></name>
<name><surname>Yajima</surname><given-names>H</given-names></name>
<name><surname>Yamao</surname><given-names>J</given-names></name>
<name><surname>Tanaka</surname><given-names>Y</given-names></name>
<name><surname>Fukui</surname><given-names>H</given-names></name>
<name><surname>Takakura</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study</article-title>. <source>Mod Rheumatol</source> <year>2009</year>; <volume>19</volume>: <fpage>629</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr26-0269216311412231">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bertsche</surname><given-names>T</given-names></name>
<name><surname>Mikus</surname><given-names>G</given-names></name>
</person-group>. <article-title>Adverse drug reactions and drug interactions in analgesic therapy</article-title>. <source>Ther Umsch</source> <year>2011</year>; <volume>68</volume>: <fpage>19</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr27-0269216311412231">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schug</surname><given-names>SA</given-names></name>
<name><surname>Manopas</surname><given-names>A</given-names></name>
</person-group>. <article-title>Update on the role of non-opioids for postoperative pain treatment</article-title>. <source>Best Pract Res Clin Anaesthesiol</source> <year>2007</year>; <volume>21</volume>: <fpage>15</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr28-0269216311412231">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanchez</surname><given-names>S</given-names></name>
<name><surname>Martin</surname><given-names>MJ</given-names></name>
<name><surname>Ortiz</surname><given-names>P</given-names></name>
<name><surname>Motilva</surname><given-names>V</given-names></name>
<name><surname>Alarcon de la Lastra</surname><given-names>C</given-names></name>
</person-group>. <article-title>Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac</article-title>. <source>Dig Dis Sci</source> <year>2002</year>; <volume>47</volume>: <fpage>1389</fpage>–<lpage>1398</lpage>.</citation>
</ref>
<ref id="bibr29-0269216311412231">
<label>29.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Riechelmann</surname><given-names>RP</given-names></name>
<name><surname>Zimmermann</surname><given-names>C</given-names></name>
<name><surname>Chin</surname><given-names>SN</given-names></name>
<etal/>
</person-group>. <article-title>Potential drug interactions in cancer patients receiving supportive care exclusively</article-title>. <source>J Pain Symptom Manage</source> <year>2008</year>; <volume>35</volume>: <fpage>535</fpage>–<lpage>543</lpage>.</citation>
</ref>
<ref id="bibr30-0269216311412231">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnitzer</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Update on guidelines for the treatment of chronic musculoskeletal pain</article-title>. <source>Clin Rheumatol</source> <year>2006</year>; <volume>25</volume>(<issue>Suppl 1</issue>): <fpage>S22</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr31-0269216311412231">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedel</surname><given-names>HA</given-names></name>
<name><surname>Fitton</surname><given-names>A</given-names></name>
</person-group>. <article-title>Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states</article-title>. <source>Drugs</source> <year>1993</year>; <volume>45</volume>: <fpage>548</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr32-0269216311412231">
<label>32.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Treudler</surname><given-names>R</given-names></name>
<name><surname>Pohle</surname><given-names>K</given-names></name>
<name><surname>Simon</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs</article-title>. <source>Eur J Clin Pharmacol</source> <year>2011</year>; <volume>00</volume>: <fpage>1</fpage>–<lpage>3</lpage> (<access-date>accessed 4 April 2011</access-date>).</citation>
</ref>
<ref id="bibr33-0269216311412231">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickerson</surname><given-names>D</given-names></name>
</person-group>. <article-title>The 20 essential drugs in palliative care</article-title>. <source>Eur J Palliat Care</source> <year>1999</year>; <volume>6</volume>: <fpage>130</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr34-0269216311412231">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simon</surname><given-names>ST</given-names></name>
<name><surname>Bausewein</surname><given-names>C</given-names></name>
</person-group>. <article-title>Management of refractory breathlessness in patients with advanced cancer</article-title>. <source>Wien Med Wochenschr</source> <year>2009</year>; <volume>159</volume>: <fpage>591</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr35-0269216311412231">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zammit</surname><given-names>G</given-names></name>
</person-group>. <article-title>Comparative tolerability of newer agents for insomnia</article-title>. <source>Drug Saf</source> <year>2009</year>; <volume>32</volume>: <fpage>735</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr36-0269216311412231">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleming</surname><given-names>JA</given-names></name>
<name><surname>Bourgouin</surname><given-names>J</given-names></name>
<name><surname>Hamilton</surname><given-names>P</given-names></name>
</person-group>. <article-title>A sleep laboratory evaluation of the long-term efficacy of zopiclone</article-title>. <source>Can J Psychiatr</source> <year>1988</year>; <volume>33</volume>: <fpage>103</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr37-0269216311412231">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vlase</surname><given-names>L</given-names></name>
<name><surname>Leucuta</surname><given-names>A</given-names></name>
<name><surname>Farcau</surname><given-names>D</given-names></name>
<name><surname>Nanulescu</surname><given-names>M</given-names></name>
</person-group>. <article-title>Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers</article-title>. <source>Biopharm Drug Dispos</source> <year>2006</year>; <volume>27</volume>: <fpage>285</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr38-0269216311412231">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>M</given-names></name>
<name><surname>Cawello</surname><given-names>W</given-names></name>
<name><surname>Boekens</surname><given-names>H</given-names></name>
<name><surname>Horstmann</surname><given-names>R</given-names></name>
</person-group>. <article-title>Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine</article-title>. <source>Br J Clin Pharmacol</source> <year>2009</year>; <volume>67</volume>: <fpage>209</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr39-0269216311412231">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brogden</surname><given-names>RN</given-names></name>
<name><surname>Carmine</surname><given-names>AA</given-names></name>
<name><surname>Heel</surname><given-names>RC</given-names></name>
<name><surname>Speight</surname><given-names>TM</given-names></name>
<name><surname>Avery</surname><given-names>GS</given-names></name>
</person-group>. <article-title>Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic</article-title>. <source>Drugs</source> <year>1982</year>; <volume>24</volume>: <fpage>360</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr40-0269216311412231">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ereshefsky</surname><given-names>L</given-names></name>
<name><surname>Jhee</surname><given-names>S</given-names></name>
<name><surname>Grothe</surname><given-names>D</given-names></name>
</person-group>. <article-title>Antidepressant drug-drug interaction profile update</article-title>. <source>Drugs R D</source> <year>2005</year>; <volume>6</volume>: <fpage>323</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr41-0269216311412231">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spina</surname><given-names>E</given-names></name>
<name><surname>Santoro</surname><given-names>V</given-names></name>
<name><surname>D’Arrigo</surname><given-names>C</given-names></name>
</person-group>. <article-title>Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update</article-title>. <source>Clin Ther</source> <year>2008</year>; <volume>30</volume>: <fpage>1206</fpage>–<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr42-0269216311412231">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stormer</surname><given-names>E</given-names></name>
<name><surname>von Moltke</surname><given-names>LL</given-names></name>
<name><surname>Shader</surname><given-names>RI</given-names></name>
<name><surname>Greenblatt</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4</article-title>. <source>Drug Metab Dispos</source> <year>2000</year>; <volume>28</volume>: <fpage>1168</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr43-0269216311412231">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walters</surname><given-names>JB</given-names></name>
<name><surname>Montagnini</surname><given-names>M</given-names></name>
</person-group>. <article-title>Current concepts in the management of opioid-induced constipation</article-title>. <source>J Opioid Manag</source> <year>2010</year>; <volume>6</volume>: <fpage>435</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr44-0269216311412231">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>SC</given-names></name>
<name><surname>Chan</surname><given-names>FK</given-names></name>
</person-group>. <article-title>NSAID-induced gastrointestinal and cardiovascular injury</article-title>. <source>Curr Opin Gastroenterol</source> <year>2010</year>; <volume>26</volume>: <fpage>611</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr45-0269216311412231">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotzsche</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Steroids and peptic ulcer: an end to the controversy?</article-title>. <source>J Intern Med</source> <year>1994</year>; <volume>236</volume>: <fpage>599</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr46-0269216311412231">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reisfield</surname><given-names>GM</given-names></name>
<name><surname>Wilson</surname><given-names>GR</given-names></name>
</person-group>. <article-title>Management of intractable, cirrhotic ascites with an indwelling drainage catheter</article-title>. <source>J Palliat Med</source> <year>2003</year>; <volume>6</volume>: <fpage>787</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr47-0269216311412231">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wargo</surname><given-names>KA</given-names></name>
<name><surname>Banta</surname><given-names>WM</given-names></name>
</person-group>. <article-title>A comprehensive review of the loop diuretics: should furosemide be first line?</article-title>. <source>Ann Pharmacother</source> <year>2009</year>; <volume>43</volume>: <fpage>1836</fpage>–<lpage>1847</lpage>.</citation>
</ref>
<ref id="bibr48-0269216311412231">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harding</surname><given-names>R</given-names></name>
<name><surname>Beynon</surname><given-names>T</given-names></name>
<name><surname>Hodson</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Provision of palliative care for chronic heart failure inpatients: how much do we need?</article-title>. <source>BMC Palliat Care</source> <year>2009</year>; <volume>8</volume>: <fpage>8</fpage>.</citation>
</ref>
<ref id="bibr49-0269216311412231">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaarsma</surname><given-names>T</given-names></name>
<name><surname>Beattie</surname><given-names>JM</given-names></name>
<name><surname>Ryder</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology</article-title>. <source>Eur J Heart Fail</source> <year>2009</year>; <volume>11</volume>: <fpage>433</fpage>–<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr50-0269216311412231">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tollefson</surname><given-names>GD</given-names></name>
</person-group>. <article-title>Antidepressant treatment and side effect considerations</article-title>. <source>J Clin Psychiatry</source> <year>1991</year>; <volume>52</volume> <supplement>Suppl</supplement>: <fpage>4</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr51-0269216311412231">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wee</surname><given-names>B</given-names></name>
<name><surname>Hillier</surname><given-names>R</given-names></name>
</person-group>. <article-title>Interventions for noisy breathing in patients near to death</article-title>. <source>Cochrane Database Syst Rev</source> <year>2008</year>: <fpage>CD005177</fpage>.</citation>
</ref>
<ref id="bibr52-0269216311412231">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wee</surname><given-names>B</given-names></name>
<name><surname>Coleman</surname><given-names>P</given-names></name>
<name><surname>Hillier</surname><given-names>R</given-names></name>
<name><surname>Holgate</surname><given-names>S</given-names></name>
</person-group>. <article-title>Death rattle: its impact on staff and volunteers in palliative care</article-title>. <source>Palliat Med</source> <year>2008</year>; <volume>22</volume>: <fpage>173</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr53-0269216311412231">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perucca</surname><given-names>E</given-names></name>
</person-group>. <article-title>Clinically relevant drug interactions with antiepileptic drugs</article-title>. <source>Br J Clin Pharmacol</source> <year>2006</year>; <volume>61</volume>: <fpage>246</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr54-0269216311412231">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nims</surname><given-names>RW</given-names></name>
<name><surname>Prough</surname><given-names>RA</given-names></name>
<name><surname>Jones</surname><given-names>CR</given-names></name>
<etal/>
</person-group>. <article-title>In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam</article-title>. <source>Drug Metab Dispos</source> <year>1997</year>; <volume>25</volume>: <fpage>750</fpage>–<lpage>756</lpage>.</citation>
</ref>
<ref id="bibr55-0269216311412231">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>EM</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Use-dependent regulation of GABAA receptors</article-title>. <source>Int Rev Neurobiol</source> <year>1996</year>; <volume>39</volume>: <fpage>53</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr56-0269216311412231">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dudra-Jastrzebska</surname><given-names>M</given-names></name>
<name><surname>Andres-Mach</surname><given-names>MM</given-names></name>
<name><surname>Sielski</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis</article-title>. <source>Eur J Pharmacol</source> <year>2009</year>; <volume>605</volume>: <fpage>87</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr57-0269216311412231">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oifa</surname><given-names>S</given-names></name>
<name><surname>Sydoruk</surname><given-names>T</given-names></name>
<name><surname>White</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery</article-title>. <source>Clin Ther</source> <year>2009</year>; <volume>31</volume>: <fpage>527</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr58-0269216311412231">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbour</surname><given-names>SY</given-names></name>
</person-group>. <article-title>Caring for the treatment-experienced breast cancer patient: the pharmacist’s role</article-title>. <source>Am J Health Syst Pharm</source> <year>2008</year>; <volume>65</volume>: <fpage>S16</fpage>–<lpage>22</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>